Evolving role of surgical treatment in limited‐disease small cell lung carcinoma

Kasi S. Sridhar; Atif M. Hussein; Richard J. Thurer

doi:10.1002/jso.2930400305

Evolving role of surgical treatment in limited‐disease small cell lung carcinoma

Kasi S. Sridhar, Atif M. Hussein, Richard J. Thurer

Surgery

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The diagnostic role of surgical procedures in small cell lung carcinoma (SCLC) is well established. The therapeutic role of surgery has changed over the years. At present, curative resection is the treatment of choice in peripheral T_1-2 N(o)M(o) SCLC, and adjuvant chemotherapy may be beneficial. Surgery is also indicated in SCLC patients diagnosed by a limited pathologic sample in whom the clinical course suggests nonsmall cell lung carcinoma (NSCLC). The resection may reveal either a mixed tumor or an alternate diagnosis and may be potentially curative. Surgery, at the time of maximal response to chemotherapy in T₃N(o)M(o) SCLC, may be curative and reveal the presence of NSCLC elements. The best survival is in patients found to be tumor-free at surgery, and the worst survival is in N₂ patients.

Original language	English (US)
Pages (from-to)	155-161
Number of pages	7
Journal	Journal of surgical oncology
Volume	40
Issue number	3
DOIs	https://doi.org/10.1002/jso.2930400305
State	Published - Mar 1989

Keywords

adjuvant surgery
histologie conversion
mixed lung tumors
multimodality therapy
preoperative chemotherapy

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.2930400305

Cite this

@article{6a57189be710440fb5ce789622e7b916,

title = "Evolving role of surgical treatment in limited‐disease small cell lung carcinoma",

abstract = "The diagnostic role of surgical procedures in small cell lung carcinoma (SCLC) is well established. The therapeutic role of surgery has changed over the years. At present, curative resection is the treatment of choice in peripheral T1-2 N(o)M(o) SCLC, and adjuvant chemotherapy may be beneficial. Surgery is also indicated in SCLC patients diagnosed by a limited pathologic sample in whom the clinical course suggests nonsmall cell lung carcinoma (NSCLC). The resection may reveal either a mixed tumor or an alternate diagnosis and may be potentially curative. Surgery, at the time of maximal response to chemotherapy in T3N(o)M(o) SCLC, may be curative and reveal the presence of NSCLC elements. The best survival is in patients found to be tumor-free at surgery, and the worst survival is in N2 patients.",

keywords = "adjuvant surgery, histologie conversion, mixed lung tumors, multimodality therapy, preoperative chemotherapy",

author = "Sridhar, {Kasi S.} and Hussein, {Atif M.} and Thurer, {Richard J.}",

year = "1989",

month = mar,

doi = "10.1002/jso.2930400305",

language = "English (US)",

volume = "40",

pages = "155--161",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Evolving role of surgical treatment in limited‐disease small cell lung carcinoma

AU - Sridhar, Kasi S.

AU - Hussein, Atif M.

AU - Thurer, Richard J.

PY - 1989/3

Y1 - 1989/3

N2 - The diagnostic role of surgical procedures in small cell lung carcinoma (SCLC) is well established. The therapeutic role of surgery has changed over the years. At present, curative resection is the treatment of choice in peripheral T1-2 N(o)M(o) SCLC, and adjuvant chemotherapy may be beneficial. Surgery is also indicated in SCLC patients diagnosed by a limited pathologic sample in whom the clinical course suggests nonsmall cell lung carcinoma (NSCLC). The resection may reveal either a mixed tumor or an alternate diagnosis and may be potentially curative. Surgery, at the time of maximal response to chemotherapy in T3N(o)M(o) SCLC, may be curative and reveal the presence of NSCLC elements. The best survival is in patients found to be tumor-free at surgery, and the worst survival is in N2 patients.

AB - The diagnostic role of surgical procedures in small cell lung carcinoma (SCLC) is well established. The therapeutic role of surgery has changed over the years. At present, curative resection is the treatment of choice in peripheral T1-2 N(o)M(o) SCLC, and adjuvant chemotherapy may be beneficial. Surgery is also indicated in SCLC patients diagnosed by a limited pathologic sample in whom the clinical course suggests nonsmall cell lung carcinoma (NSCLC). The resection may reveal either a mixed tumor or an alternate diagnosis and may be potentially curative. Surgery, at the time of maximal response to chemotherapy in T3N(o)M(o) SCLC, may be curative and reveal the presence of NSCLC elements. The best survival is in patients found to be tumor-free at surgery, and the worst survival is in N2 patients.

KW - adjuvant surgery

KW - histologie conversion

KW - mixed lung tumors

KW - multimodality therapy

KW - preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0024596914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024596914&partnerID=8YFLogxK

U2 - 10.1002/jso.2930400305

DO - 10.1002/jso.2930400305

M3 - Article

C2 - 2537443

AN - SCOPUS:0024596914

VL - 40

SP - 155

EP - 161

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -

Evolving role of surgical treatment in limited‐disease small cell lung carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this